- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04776629
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
Study Overview
Status
Intervention / Treatment
Detailed Description
This randomized, double-blind, study is designed to compare the effect of orticumab against placebo in subjects with moderate to severe psoriasis and cardiometabolic risk factors. A total of 75 subjects will be randomized in a double-blind fashion to receive intravenous (IV) infusions either of orticumab or placebo for up to 78 days.
Participants will be enrolled into one of the two groups: active treatment or placebo. Subjects will be randomized in a 2:1 ratio, orticumab to placebo and receive up to 11 weeks of treatment.
Planned treatments are weekly x 4 , then monthly x 2 . The Internal Safety Review Committee (ISRC) will review the blinded safety data after the first subject completes the first dose (Day 1), the first five subjects complete the first dose (Day 1), and the first ten subjects complete the first dose (Day 1). The IRSC will review all adverse reactions to all administered doses at these times.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- CCT- Research at the center for Dermatology and Plastic Surgery
-
-
California
-
Santa Monica, California, United States, 90404
- Derm Institute & Skin Care Ctr., Inc.
-
Tustin, California, United States, 92780
- Orange County Research Center
-
Vista, California, United States, 92083
- Blue Coast Research Center
-
-
Florida
-
Jacksonville, Florida, United States, 32216
- Jacksonville Center for Clinical Research
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Dawes Fretzin Clinical Research Group, LLC
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109
- Excel Clinical Research
-
Las Vegas, Nevada, United States, 89030
- Las Vegas Clinical Trials
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 85260
- Vital Prospects Clinical Research Institute, PC
-
-
Texas
-
Mesquite, Texas, United States, 75149
- SMS Clinical Research
-
San Antonio, Texas, United States, 78218
- Texas Dermatology and Laser Specialists
-
Webster, Texas, United States, 77598
- Center for Clinical Studies, LTD.LLP
-
-
Utah
-
Springville, Utah, United States, 84663
- CCT Research - Springville Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Stable/chronic plaque psoriasis with PASI score of ≥ 12 AND involving ≥ 10% of the subject's BSA.- ≥ 30 years of age at time of consent.
- BMI ≥ 30 kg/m2
- LDL ≥ 100 mg/dL at Screening.
- All females must have a negative serum pregnancy test result at Screening and a negative urine pregnancy test prior to dosing.
Exclusion Criteria:
Subjects are excluded from the study if any of the following criteria are met:
- Past use of orticumab.
- Any of the nonplaque forms of psoriasis: erythrodermic, guttate, or pustular.
- Scalp, palmar or plantar psoriasis only, at Screening or Baseline.
- Have evidence of skin conditions (e.g., eczema) at the time of Screening or Baseline visit that would interfere with theevaluation of psoriasis.
- Newly discovered Type 2 diabetes mellitus (T2DM)
- Moderate or high-intensity statin use or new use of a low-intensity statin therapy.
- No use of anti-coagulating or anti-thrombotic agents.
- Poorly controlled hypertension
- Use of an IL-23 blocker in the past 180 days, an IL-17 blocker in the past 16 weeks, or a TNF blocker in the past 12 weeks.
- Use of methotrexate, cyclosporine, or apremilast in the past 4 weeks.
- History of hypersensitivity or allergies to any contents in the orticumab formulation.
- A history of any clinically important abnormalities in cardiac rhythm or conduction.
- A history of prolonged QT intervals or a family history of long QT-syndrome at Screening.
- A history of first, second or third-degree atrioventricular (AV) block, or AV dissociation.
- A history of complete bundle branch block.
- Unstable angina pectoris, myocardial infarction, transient ischemic attack, or stroke within 3 months prior to Screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within 6 months prior to Screening or who are due to undergo these procedures at the time of Screening.
- Severe congestive heart failure (NYHA III or IV).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Treatment
Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes. Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months. |
A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope
Other Names:
|
Placebo Comparator: Placebo
Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes. Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months. |
Placebo for orticumab, containing all components of formulation except the active ingredient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean percent change from Baseline in Psoriasis Area Severity Index (PASI)
Time Frame: 106 days (Week 15)
|
PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)
|
106 days (Week 15)
|
Percentage of participants achieving treatment success by the 5-point static Investigator's Global Assessment modified 2011 version (sIGA) Score
Time Frame: 106 days (Week 15)
|
Percentage of participants achieving treatment success (clear =0 or almost clear =1) and greater than or equal to (>=) 2 Point Improvement at Week 15 on the sIGA scale
|
106 days (Week 15)
|
Incidence of Treatment Emergent Adverse Events (TEAEs)
Time Frame: 106 days (Week 15)
|
106 days (Week 15)
|
|
Incidence of serious adverse events (SAEs)
Time Frame: 106 days (Week 15)
|
106 days (Week 15)
|
|
Incidence of abnormal hemodynamic parameters
Time Frame: Weeks 3, 7, 11 and 15
|
heart rate (HR) and blood pressure (BP)
|
Weeks 3, 7, 11 and 15
|
Incidence of abnormal laboratory tests results
Time Frame: Weeks 3 and 15
|
Weeks 3 and 15
|
|
Incidence of abnormal physical examination findings
Time Frame: Weeks 3, 7, 11, 15
|
Physical examination will include the following organ or body system assessments: general appearance; eyes; ears, nose, and throat; head and neck; chest and lungs; cardiovascular; abdomen; musculoskeletal; lymphatic; dermatological; neurological; and extremities.
|
Weeks 3, 7, 11, 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean percent change from Baseline in Psoriasis Area Severity Index (PASI)
Time Frame: Weeks 1, 3, 7, and 11
|
PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)
|
Weeks 1, 3, 7, and 11
|
Percentage of Participants achieving PASI75 and PASI50
Time Frame: Weeks 1, 3, 7, and 11
|
PASI75 is a 75 percent reduction in PASI score.
PASI50 is a 50 percent reduction in PASI score
|
Weeks 1, 3, 7, and 11
|
Mean percent change in Baseline in Body Surface Area (BSA) % involvement
Time Frame: Weeks 1, 3, 7, 11, 15
|
Minimum: 0 percent, Maximum: 100 percent.
Higher percentage indicates more skin with psoriasis.
|
Weeks 1, 3, 7, 11, 15
|
Mean change from Baseline in Dermatology Life Quality Index (DLQI) score
Time Frame: Weeks 3, 7, 11, 15
|
DLQI is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person.
Each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).
|
Weeks 3, 7, 11, 15
|
Mean change from Baseline in Itch Numerical Rating Scale (INRS) Score
Time Frame: Weeks 3 and 15
|
The Itch NRS is a self-administered subject reported outcome questionnaire that is completed during protocol specified clinic visits.
Participants indicate itch severity by circling the integer that best describes the worst level of itching due to psoriasis in the past 24 h on an 11-point scale anchored at 0, representing 'no itching' and 10, representing 'worst itch imaginable'.
|
Weeks 3 and 15
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Coronary Artery Inflammation by CCTA
Time Frame: 106 days (Week 15)
|
Change in coronary artery perivascular fat attenuation index (FAI) measured by coronary computed tomographic angiography (CCTA)
|
106 days (Week 15)
|
Change in coronary artery plaque burden by CCTA
Time Frame: 106 days (Week 15)
|
Change in total, noncalcified and low attenuation coronary artery plaque volume
|
106 days (Week 15)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joel Neutel, MD, Orange County Research Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Skin Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Skin Diseases, Papulosquamous
- Insulin Resistance
- Hyperinsulinism
- Coronary Disease
- Coronary Artery Disease
- Inflammation
- Psoriasis
- Metabolic Syndrome
Other Study ID Numbers
- Ort-2020-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina